Argenx cans Phase III Vyvgart Sjögren's study on predicted efficacy fail

Aside from Vyvgart's Sjögren's fail, Argenx is eyeing further label expansion for Vyvgart Hytrulo across several immunological indications. Argenx is currently eyeing further label expansion for Vyvgart Hytrulo across several immunological indications. Argenx discontinued UNITY following a recommendation from the independent data monitoring committee. Credit: Vitalii Vodolazskyi / Shutterstock.com. Argenx has terminated a late-stage trial evaluating its marketed therapy, Vyvgart Hytrulo (efgartigimod alfa, hyaluronidase-qvfc) in Sjögren’s syndrome – dashing the drug’s hopes of a label expansion in this indication. The Dutch biotech made the call to discontinue the Phase III UNITY study (NCT06684847) based on recommendations from the trial’s independent…

Source: Clinical Trials Arena